share_log

Amgen Records Slight Fall In Quarterly Earnings; Lower COVID-19 Manufacturing Pacts Impact Bottomline

Amgen Records Slight Fall In Quarterly Earnings; Lower COVID-19 Manufacturing Pacts Impact Bottomline

安进的季度收益略有下降；COVID-19 制造协议的降低影响了利润
Benzinga Real-time News ·  2023/02/01 07:43
  • Amgen Inc's (NASDAQ:AMGN) fourth-quarter revenues were $6.84 billion, beating the consensus of $6.76 billion, largely unchanged from Q4 2021, and benefited from a 4% increase in product sales, offset by lower COVID-19 manufacturing collaboration revenues.
  • Product sales growth was driven by 10% volume growth, partially offset by a 3% lower net selling price and a 2% negative impact from foreign exchange. Excluding the 2% negative impact of foreign exchange on product sales, total revenues increased by 2%.
  • The company's listed "other revenue," which includes the manufacturing deal, fell to $287 million from $575 million last year.
  • Adjusted earnings per share decreased to $4.09 from $4.40 a year ago, in line with the consensus estimates.
  • Amgen product sales were led by a 14% jump in osteoporosis drug Prolia to a quarterly record of $992 million.
  • Guidance: Amgen expects 2023 revenue of $26-$27.2 billion, excluding the impact of its anticipated acquisition of Horizon Therapeutics Plc (NASDAQ:HZNP), versus the consensus of $27.3 billion.
  • "The announced acquisition of Horizon Therapeutics, which we expect to complete in the first half of this year, represents a compelling opportunity to serve more patients and strengthen our growth profile," Amgen Chief Executive Robert Bradway said.
  • The company forecasts adjusted EPS of $17.40-$18.60 versus the consensus of $18.33.
  • Earlier Tuesday, Amgen launched Amjevita, the first U.S. biosimilar of AbbVie Inc's (NYSE: ABBV) arthritis treatment Humira that the FDA approved in 2016.
  • Price Action: AMGN shares are down 0.95% at $250 during the premarket session on the last check Wednesday.
  • 安进公司的 纳斯达克股票代码：AMGN）第四季度收入为68.4亿美元，超过了共识的67.6亿美元，与 2021 年第四季度基本保持不变，受益于产品销售增长 4%，但被 COVID-19 制造合作收入的减少所抵消。
  • 产品销售增长是由10％的销量增长推动的，但部分被净销售价格下降3％和外汇带来的2％的负面影响所抵消。不包括外汇对产品销售的2％的负面影响，总收入增长了2％。
  • 该公司上市的 “其他收入”，包括制造协议，从去年的5.75亿美元降至2.87亿美元。
  • 调整后的每股收益从去年同期的4.40美元降至4.09美元，符合共识预期。
  • 骨质疏松症药物Prolia增长了14％，达到创纪录的9.92亿美元，带动了安进产品销售。
  • 指导: 安进预计2023年的收入为26-272亿美元，不包括其预期收购的影响 地平线疗法有限公司 纳斯达克股票代码：HZNP），而共识为273亿美元。
  • 安进首席执行官罗伯特·布拉德威说：“宣布对Horizon Therapeutics的收购预计将于今年上半年完成，这为服务更多患者和加强我们的增长形势提供了一个难得的机会。”
  • 该公司预测调整后的每股收益为17.40美元至18.60美元，而共识为18.33美元。
  • 周二早些时候，安进推出了Amjevita，这是美国第一款生物仿制药 AbbVie Inc's （纽约证券交易所股票代码：ABBV）关节炎治疗Humira于2016年获得美国食品药品管理局的批准。
  • 价格走势： 在周三的最后一次盘前交易中，AMGN股价下跌0.95％，至250美元。
声明：本内容仅用作提供资讯及教育之目的，不构成对任何特定投资或投资策略的推荐或认可。 更多信息
    抢沙发